Market Insights

Eli Lilly's announcement that it is capping the cost of insulin at $35 a month also casts light on pharmacy benefit managers at a time when Congress has shifted its focus on them.

The survey revealed a more positive outlook and insight into their obstacles and intentions for 2023.

Stakeholders may need to consider whether antitrust enforcement agencies will implement a 'cross-market' theory of competitive harm.

In 2020, national spending on health care increased 9.7% to $4.1 trillion, more than double the increase in 2019.

Benefits advisors and brokerages of all sizes must band together and learn from each other in order to move the industry forward and create meaningful change.

New data suggests workers are becoming more confident in seeking new opportunities elsewhere, too.